JZP 386

Drug Profile

JZP 386

Alternative Names: C-10323; Deuterated sodium oxybate - Concert Pharmaceuticals/Jazz Pharmaceuticals; Deuterium modified sodium oxybate - Concert Pharmaceuticals/Jazz Pharmaceuticals; JZP386; Sodium oxybate deuterated - Concert Pharmaceuticals/Jazz Pharmaceuticals

Latest Information Update: 20 Apr 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Concert Pharmaceuticals
  • Developer Concert Pharmaceuticals; Jazz Pharmaceuticals plc
  • Class Hydroxybutyrates; Organic deuterium compounds; Sleep disorder therapies; Small molecules
  • Mechanism of Action Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Narcolepsy

Most Recent Events

  • 30 Sep 2014 Concert Pharmaceuticals completes enrolment in its phase I trial for Narcolepsy (In volunteers) in United Kingdom before September 2014 (NCT02215499,
  • 21 Jul 2014 Phase-I clinical trials in Narcolepsy (In volunteers) in United Kingdom (PO)
  • 31 Jan 2014 European regulatory authorities approve Investigational Medicinal Product Dossier for JZP 386 in Narcolepsy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top